Tag: transfer

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Inflection Point Acquisition Corp. III (Nasdaq: IPCXU) (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the exercise by the underwriters of their overallotment option, completed on April 28, 2025 (the “Offering”) may elect to separately trade the Class A ordinary shares and rights included in the units commencing on or about June 16, 2025. Any units not separated will continue to trade on The Nasdaq Global Market under the symbol “IPCXU”, and each of the Class A ordinary shares and rights will separately trade on The Nasdaq Global Market under the symbols “IPCX” and “IPCXR,” respectively. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and rights.

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.

DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, is pleased to announce a change to its regular dividend payment frequency from quarterly to monthly beginning in July 2025.

WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of Biofrontera AG on June 10, 2025, according to which the two companies are in negotiations regarding a possible combination of the two companies or an adjustment of the license and supply agreement between them. The latter could result in the transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and a reduction in the transfer price for Biofrontera Inc.’s licensed products sold in the US.

New York City, June 11, 2025 (GLOBE NEWSWIRE) -- Financial crises impact millions of Americans each year, too often leaving people with poor credit choices navigating for instant funding alternatives. Low Credit Finance, an online lending marketplace, has created a $500 loan product tailored to subprime borrowers who have poor credit records. The product takes advantage of the increased need for affordable emergency lending among consumers who do not qualify for conventional bank loans.

New York City, NJ, June 11, 2025 (GLOBE NEWSWIRE) --

Wizzay.com has announced improvements to its web-based lending platform, allowing consumers to obtain 1 hour payday loans through a network of partner lenders. The platform establishes borrowers in contact with direct lender partners who offer payday loans no credit check, guaranteeing same day funding for emergency cash needs. The service responds to increasing consumer demand for expedited access to short-term financial options without conventional credit checks.

PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid’s D-PLEX100 as Potential New Standard of Care in the Future

Strasbourg, France and Charleroi, Belgium, June 11^th  2025 – Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic agents to treat depression and other neuropsychiatric condition, announced today that it has closed an oversubscribed EUR 11.25 million Seed funding round. The round was co-led by Kurma Partners, WE Life Sciences and the French Tech Seed fund managed on behalf of the French government by Bpifrance as part of France 2030, with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est and Sambrinvest. Elkedonia is bringing together stakeholders from across the European ecosystem, with headquarters in Strasbourg, France and an affiliate in Charleroi, Belgium.